Lin et al., 2022 - Google Patents
Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseasesLin et al., 2022
View PDF- Document ID
- 3207057467461763326
- Author
- Lin S
- Mao R
- Qian C
- Bettenworth D
- Wang J
- Li J
- Bruining D
- Jairath V
- Feagan B
- Chen M
- Stenosis Therapy and Antifibrotic Research (STAR) Consortium
- Rieder F
- Publication year
- Publication venue
- Physiological reviews
External Links
Snippet
Intestinal fibrosis is considered an inevitable complication of Crohn's disease (CD) that results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment is required to treat the majority of patients. Progress in the management of stricturing CD is …
- 206010011401 Crohn's disease 0 title abstract description 155
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases | |
| Ferrucci et al. | Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty | |
| D’Alessio et al. | Revisiting fibrosis in inflammatory bowel disease: the gut thickens | |
| Wang et al. | The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation | |
| Breyer et al. | The next generation of therapeutics for chronic kidney disease | |
| Goette et al. | Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation | |
| McCoy et al. | Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta | |
| Boor et al. | Treatment targets in renal fibrosis | |
| Eirin et al. | Inflammatory and injury signals released from the post-stenotic human kidney | |
| Fury et al. | Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance | |
| US20080003199A1 (en) | IL-33 in the treatment and diagnosis of diseases and disorders | |
| Asano et al. | The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis | |
| US20130316337A1 (en) | Methods of Diagnosing and Treating an Inflammatory Response | |
| Mori et al. | Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice | |
| Bamias et al. | Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis | |
| Garlapati et al. | Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF-β1–driven fibrotic remodeling in ischemic heart failure | |
| Hermansson et al. | Macrophage CD14 expression in human carotid plaques is associated with complicated lesions, correlates with thrombosis, and is reduced by angiotensin receptor blocker treatment | |
| Jiang et al. | Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis | |
| Yoshiji et al. | Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development | |
| Li et al. | Neutrophil extracellular traps promote macrophage inflammation in psoriasis | |
| Zhang et al. | Empagliflozin inhibits neointimal hyperplasia through attenuating endothelial-to-mesenchymal transition via TAK-1/NF-κB pathway | |
| Zhang et al. | Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells | |
| EP3195881A1 (en) | Substance that inhibits p2y12 receptor, for use in the preventive treatment of systemic sclerosis in patients with raynaud's phenomenon and a dysimmunity | |
| JP2020531539A (en) | Use of canakinumab | |
| Colin et al. | The Antiangiogenic Insulin Receptor Substrate-1 Antisense Oligonucleotide Aganirsen Impairs AU-Rich mRNA Stability by Reducing 14-3-3β–Tristetraprolin Protein Complex, Reducing Inflammation and Psoriatic Lesion Size in Patients |